Loading...

BNTC

BNTX

BIONTECH SE

(BNTX)

2025 6-K

Share Repurchase Program

7 May '26

Quarterly Financial Update

5 May '26

Earnings Announcement

5 May '26

Positive Trial Results

13 Apr '26

Annual Meeting Notice

2 Apr '26

Cancer Data Presentation

24 Mar '26

BioNTech Financial Results

10 Mar '26

New Company Launch

10 Mar '26

Management Appointment

28 Jan '26

Business Update

13 Jan '26

Business Update

12 Jan '26

CureVac Acquisition

6 Jan '26

CureVac Acquisition

18 Dec '25

Clinical Trial Update

9 Dec '25

Clinical Data Update

8 Dec '25

CureVac Exchange Offer

3 Dec '25

CureVac Exchange Update

26 Nov '25

R&D Day Overview

12 Nov '25

Quarterly Update

3 Nov '25

Q3 Earnings Report

3 Nov '25

Share Exchange Offer

22 Oct '25

AI Day Overview

1 Oct '25

Positive Trial Results

8 Sep '25

Collaboration Agreement

8 Sep '25

Trial Success Announced

5 Sep '25

FDA Approval Announcement

27 Aug '25

Patent Settlement Update

11 Aug '25

Financial Update

4 Aug '25

BioNTech Q2 Results

4 Aug '25

COVID-19 Vaccine Approval

25 Jul '25

Management Change

17 Jul '25

Articles Filed

17 Jun '25

Acquisition Announcement

17 Jun '25

Strategic Acquisition

12 Jun '25

Strategic Partnership

2 Jun '25

Clinical Trial Announcement

27 May '25

R&D Expansion

20 May '25

Annual Meeting Update

16 May '25

Financial Results Update

5 May '25

Q1 2025 Results

5 May '25

Management Change

5 May '25

Oncology Pipeline Data

24 Apr '25

Annual Meeting Notice

4 Apr '25

Settlement Agreement

2 Apr '25

2024 Financial Results

10 Mar '25

FDA Clinical Hold

4 Mar '25

Acquisition Completed

3 Feb '25

Strategic Priorities Update

14 Jan '25

Settlement Agreement

27 Dec '24

Settlement Agreement

27 Dec '24

FDA Hold Lifted

13 Dec '24

Innovation Series Day

14 Nov '24

Acquisition Announcement

13 Nov '24

BioNTech Update

4 Nov '24

Q3 Financial Results

4 Nov '24

Clinical Hold Update

18 Oct '24

AI Day Presentation

1 Oct '24

Vaccine Approval Update

20 Sep '24

Clinical Trial Presentation

5 Sep '24

FDA Approval Granted

22 Aug '24

FDA Hold Lifted

19 Aug '24

Vaccine Update

16 Aug '24

Lawsuit Announcement

6 Aug '24

Financial Update

5 Aug '24

Earnings Release

5 Aug '24

Positive Trial Results

30 Jul '24

Vaccine Authorization Update

27 Jun '24

FDA Fast Track Approval

24 Jun '24

FDA Hold Announcement

17 Jun '24

Phase 2 Trial Results

3 Jun '24

Partnership Expansion

29 May '24

Clinical Trial Data

21 May '24

AGM Results Approved

17 May '24

Quarterly Report

6 May '24

Financial Results Update

6 May '24

Annual Meeting Notice

8 Apr '24

Immunotherapy Update

8 Apr '24

NIH Notice Received

22 Mar '24

BioNTech Update

20 Mar '24

Management Appointment

20 Mar '24

Clinical Data Presentation

11 Mar '24

Management Change

7 Mar '24

Strategic Collaboration

8 Feb '24

FDA Fast Track Granted

31 Jan '24

Clinical Trial Update

22 Jan '24

2024 Strategic Priorities

9 Jan '24

External Links:

SEC

On November 26, 2025, BioNTech SE announced details regarding the exchange offer for CureVac shares, which includes the results of CureVac’s extraordinary meeting and the exchange ratio calculation.

AI Assistant

BIONTECH SE

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.